博拓生物
(688767)
| 流通市值：10.23亿 | | | 总市值：27.10亿 |
| 流通股本：4026.67万 | | | 总股本：1.07亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 135,626,648.51 | 442,110,404.25 | 312,238,836.62 | 212,076,278.09 |
| 营业收入 | 135,626,648.51 | 442,110,404.25 | 312,238,836.62 | 212,076,278.09 |
| 二、营业总成本 | 91,142,982.46 | 298,968,264.87 | 216,468,676.37 | 141,907,867.85 |
| 营业成本 | 74,822,867.8 | 219,590,245.23 | 181,379,844.01 | 125,119,825.35 |
| 税金及附加 | 1,348,082.07 | 5,455,337.33 | 4,114,659.4 | 3,919,314.74 |
| 销售费用 | 4,488,401.71 | 27,882,758.92 | 17,075,787.92 | 11,063,337.63 |
| 管理费用 | 13,005,826.89 | 51,325,909.73 | 36,879,430.49 | 23,326,173.27 |
| 研发费用 | 14,645,403.84 | 80,475,253.93 | 43,745,658.93 | 28,589,095.22 |
| 财务费用 | -17,167,599.85 | -85,761,240.27 | -66,726,704.38 | -50,109,878.36 |
| 其中:利息费用 | - | 136,617.26 | - | - |
| 其中:利息收入 | - | 73,525,036.35 | - | - |
| 加:公允价值变动收益 | - | 0 | -64,516.13 | -64,516.13 |
| 加:投资收益 | -271,329.44 | 3,379,945.24 | 3,744,810.35 | 3,355,550.09 |
| 资产处置收益 | -49,756.6 | 2,262.49 | -103,665.76 | -104,518.57 |
| 资产减值损失(新) | -405,996.24 | -55,274,643.2 | -7,802,423.84 | -7,678,902.64 |
| 信用减值损失(新) | 236,675.18 | -3,561,762.73 | -2,942,831.02 | -2,210,875.88 |
| 其他收益 | 541,941.93 | 29,135,732.03 | 2,492,271.81 | 1,830,714.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 44,535,200.88 | 116,823,673.21 | 91,093,805.66 | 65,295,861.43 |
| 加:营业外收入 | 2,691.48 | 608,146.95 | 12,709,035.4 | 4,770,982.3 |
| 减:营业外支出 | 1,254.41 | 1,554,722.69 | 340,854.83 | 76.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 44,536,637.95 | 115,877,097.47 | 103,461,986.23 | 70,066,767.17 |
| 减:所得税费用 | 5,002,305.82 | 10,577,296.76 | 13,401,020.59 | 9,103,761.7 |
| 六、净利润 | 39,534,332.13 | 105,299,800.71 | 90,060,965.64 | 60,963,005.47 |
| 持续经营净利润 | 39,534,332.13 | 105,299,800.71 | 90,060,965.64 | 60,963,005.47 |
| 归属于母公司股东的净利润 | 39,631,348.59 | 106,605,811.85 | 91,527,900.55 | 61,602,889.28 |
| 少数股东损益 | -97,016.46 | -1,306,011.14 | -1,466,934.91 | -639,883.81 |
| (一)基本每股收益 | 0.38 | 1 | 0.86 | 0.58 |
| (二)稀释每股收益 | 0.38 | 1 | 0.86 | 0.58 |
| 八、其他综合收益 | 256,146.39 | -1,569,443.72 | 1,016,527.73 | 1,144,351.85 |
| 归属于母公司股东的其他综合收益 | 250,178.88 | -1,564,632.29 | 914,874.95 | 1,029,916.67 |
| 九、综合收益总额 | 39,790,478.52 | 103,730,356.99 | 91,077,493.37 | 62,107,357.32 |
| 归属于母公司股东的综合收益总额 | 39,881,527.47 | 105,041,179.56 | 92,442,775.5 | 62,632,805.95 |
| 归属于少数股东的综合收益总额 | -91,048.95 | -1,310,822.57 | -1,365,282.14 | -525,448.63 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |